Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Multinomial network meta-analysis using response rates: relapsed/refractory multiple myeloma treatment rankings differ depending on the choice of outcome

Fig. 1

Network of relapsed/refractory MM RCTs used for the multinomial network meta-analysis based on response. Legend: format of dark grey results box = `RCT name’: %CR/%PR/% < PR (N = `total number of patients’), * indicates estimated from other values, and black box indicates the reference treatment. Abbreviations: WB WinBUGS, NMA result, Bo bortezomib, Dex dexamethasone, Tha thalidomide, Car carfilzomib, Obl oblimersen, Dara daratumumab, Len lenalidomide, Pom pomalidomide, Ixa ixazomib, Elo elotuzumab, Pano panobinostat, Vorino = vorinostat, PLD pegylated liposomal doxorubicin

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us